The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy ...
Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...
Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, ...
Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who ...
Medical Device Network on MSN
Prodeon Medical’s BPH implant gains FDA clearance
In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score ...
Image courtesy of Prodeon Medical] Prodeon Medical announced today that it received FDA 510(k) clearance for its Urocross ...
Early-stage prostate cancer rarely causes symptoms, making routine screening the most reliable way to catch it before it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results